Table 6.

Sensitivity analysis for different model parameter assumptions: overview of colorectal cancer screening strategies that are cost saving in the near-future scenario^*

Model assumption†	High value	Low value
Progression rate of adenomas	Hemoccult II, immunochemical FOBT	All strategies except colonoscopy
Colorectal cancer risk	All strategies	Hemoccult II
Colonoscopy costs	Hemoccult II	All strategies
Costs of new chemotherapies	All strategies except colonoscopy	Hemoccult II, immunochemical FOBT, flexible sigmoidoscopy
Discount rate	Hemoccult II	All strategies
% of patients who get new chemotherapies	NA	Hemoccult II, immunochemical FOBT, flexible sigmoidoscopy

^*FOBT = fecal occult blood test; NA = not applicable.

^†Adenoma progression rate: low value = half the base case value, high value = double the base case value; Colorectal cancer risk: low value = half the base case risk, high value = double the base case risk; Colonoscopy costs: low value = 25% lower than the base case, high value = 25% higher than the base case; Costs of new chemotherapies: low value = 25% lower than the base case, high value = 25% higher than the base case; Discount rate: low value = 0%, high value = 5%; % of patients who get new chemotherapies: low value = 75%.